Ascletis Pharma (OTCMKTS:ASCLF) Stock Price Down 12.7% – Should You Sell?

Ascletis Pharma Inc. (OTCMKTS:ASCLF – Get Free Report)’s share price was down 12.7% on Tuesday . The company traded as low as $1.67 and last traded at $1.87. Approximately 7,500 shares were traded during mid-day trading, an increase of 163% from the average daily volume of 2,852 shares. The stock had previously closed at $2.1420.

Ascletis Pharma Price Performance

The stock’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $1.84.

Ascletis Pharma Company Profile

(Get Free Report)

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

See Also

• Five stocks we like better than Ascletis Pharma
• HIVE Weaponizes Power for an AI Pivot
• A Deep Dive Into NVIDIA’s Latest Portfolio Moves
• Brady Corp Wires Up a Massive AI-Powered Breakout
• Why Home Depot’s Sell-Off Could Become a Huge Opportunity